Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00306566 | Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients | completed | Phase 1 / Phase 2 | — | Cytos Biotechnology AGINDUSTRY | 1 | Sep 20, 2007 | clinicaltrials |
| NCT00232726 | Clinical Study of Previously Untreated Patients With Malignant Melanoma | completed | Phase 2 | 42 | Clavis PharmaINDUSTRY | 3 | Jul 10, 2007 | clinicaltrials |
| NCT00083239 |
| Study of Talabostat in Advanced Melanoma |
| completed |
| Phase 2 |
| — |
| Point TherapeuticsINDUSTRY |
| 1 |
| Jun 8, 2007 |
| clinicaltrials |
| NCT00083252 | Study of Talabostat and Cisplatin in Advanced Melanoma | completed | Phase 2 | — | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
| NCT00204607 | Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | University Hospital TuebingenOTHER | 1 | Apr 19, 2007 | clinicaltrials |
| NCT00306553 | Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients | completed | Phase 2 | — | Cytos Biotechnology AGINDUSTRY | 1 | Sep 19, 2006 | clinicaltrials |
| NCT00350597 | GM-CSF as Adjuvant Therapy of Melanoma | completed | Phase 2 | 50 | Northern California Melanoma CenterOTHER | 1 | Jul 11, 2006 | clinicaltrials |
| NCT00188370 | Ultrasound Biomicroscopy - Apoptosis | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Sep 16, 2005 | clinicaltrials |
| NCT00041808 | Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver | completed | Phase 1 / Phase 2 | 20 | FeRxINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
| NCT00055562 | Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma | completed | Phase 2 / Phase 3 | 274 | Celgene CorporationINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Sep 20, 2007source: clinicaltrials